Claims for Patent: 10,940,116

Summary for Patent: 10,940,116

Title:	Delayed release deferiprone tablets and methods of using the same
Abstract:	The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.
Inventor(s):	Sherman; Bernard Charles (Toronto, CA), Spino; Michael (Pickering, CA)
Assignee:	Chiesi Farmaceutici S.p.A. (Parma, IT)
Application Number:	16/171,170
Patent Claims:	1. A delayed release tablet for oral administration comprising: (a) a core comprising about 1000 mg deferiprone and an enteric polymer; and (b) an enteric coating comprising an enteric polymer, wherein the tablet is suitable for twice daily dosing. 2. The tablet of claim 1 which is scored to facilitate breakage of the tablet into half tablets. 3. The tablet of claim 2 which can be administered as one or more whole tablets, one or more half tablets, or a combination thereof. 4. The tablet according to claim 1, wherein the enteric polymer in the core is selected from the group consisting of hydroxypropyl methylcellulose acetate succinate (HPMCAS), HPMC phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, a derivative thereof, and a combination thereof. 5. The tablet according to claim 4, wherein the enteric polymer is present in an amount of about 1% to about 20% by weight of the core. 6. The tablet according to claim 1, wherein the enteric polymer in the enteric coating is selected from the group consisting of hydroxypropyl methylcellulose acetate succinate (HPMCAS), HPMC phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, a derivative thereof, and a combination thereof. 7. The tablet according to claim 1, wherein a single dose of the 1000 mg tablet provides a mean AUCI/C.sub.max ratio between 3.5 hours and 6.0 hours when the tablet is administered to human subjects in a fasted state. 8. The tablet according to claim 1, wherein a single dose of the 1000 mg tablet provides a mean AUCI/C.sub.max ratio between 3.5 hours and 6.0 hours when the tablet is administered to human subjects in a fed state. 9. The tablet according to claim 1, wherein a single dose of the 1000 mg tablet provides a mean C.sub.max between 2.670 and 13.232 .mu.g/mL when the tablet is administered to human subjects in a fasted state. 10. The tablet according to claim 1, wherein the median T.sub.max is between 1.33 and 4.00 hours when the tablet is administered to human subjects in a fasted state. 11. The tablet according to claim 1, wherein the median T.sub.max is between 2.00 and 8.00 hours when the tablet is administered to human subjects in a fed state. 12. The tablet according to claim 1, wherein a single dose of the 1000 mg tablet provides a ratio of AUCI/C.sub.max between 2.858 to 6.596 hours when the tablet is administered to human subjects in a fasted state. 13. The tablet according to claim 1, wherein a single dose of the 1000 mg tablet provides a ratio of AUCI/C.sub.max between 3.225 to 8.506 hours when the tablet is administered to human subjects in a fed state. 14. The tablet according to claim 1, wherein the tablet releases less than about 80% of the deferiprone within 60 minutes when measured by USP Apparatus Type II Paddle Method at 75 rpm in 900 mL water at 37.+-.0.5.degree. C. 15. The tablet according to claim 1, wherein a single dose of the 1000 mg tablet provides a mean C.sub.max between 2.908 and 9.514 .mu.g/mL when the tablet is administered to human subjects in a fed state. 16. A tablet comprising deferiprone for twice daily oral administration, wherein a single dose administration of the tablet provides a mean AUCI/C.sub.max ratio between 3.5 hours and 6.0 hours in both fasted and fed state when the tablet is administered as a whole tablet and when administered as a half tablet to human subjects, and wherein the tablet comprises a core comprising about 1000 mg of deferiprone, about 20 mg to about 80 mg of an enteric polymer, and about 5 mg to about 100 mg of a basic excipient, wherein the tablet is suitable for dissolution in the duodenum. 17. The tablet according to claim 16, wherein a single dose of the 1000 mg tablet provides a mean C.sub.max between 2.670 and 13.232 .mu.g/mL when the tablet is administered to human subjects in a fasted state. 18. The tablet according to claim 16, wherein the median T.sub.max is between 1.33 and 4.00 hours when the tablet is administered to human subjects in a fasted state. 19. The tablet according to claim 16, wherein the median T.sub.max is between 2.00 and 8.00 hours when the tablet is administered to human subjects in a fed state. 20. The tablet according to claim 16, wherein the tablet releases less than about 80% of the deferiprone within 60 minutes when measured by USP Apparatus Type II Paddle Method at 75 rpm in 900 mL water at 37.+-.0.5.degree. C. 21. The tablet according to claim 16, wherein the enteric polymer in the core is selected from the group consisting of hydroxypropyl methylcellulose acetate succinate (HPMCAS), HPMC phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, a derivative thereof, and a combination thereof. 22. The tablet according to claim 16, wherein the enteric polymer in the enteric coating is selected from the group consisting of hydroxypropyl methylcellulose acetate succinate (HPMCAS), HPMC phthalate, polyvinyl acetate phthalate, methacrylic acid copolymers, a derivative thereof, and a combination thereof. 23. The tablet according to claim 16, wherein a single dose of the 1000 mg tablet provides a mean C.sub.max between 2.908 and 9.514 .mu.g/mL when the tablet is administered to human subjects in a fed state.